دورية أكاديمية
أعرض في EDS

Integration of TE Induces Cancer Specific Alternative Splicing Events.

التفاصيل البيبلوغرافية
العنوان: Integration of TE Induces Cancer Specific Alternative Splicing Events.
المؤلفون: Kim WR; Department of Integrated Biological Sciences, Pusan National University, Busan 46241, Korea.; Institute of Systems Biology, Pusan National University, Busan 46241, Korea., Park EG; Department of Integrated Biological Sciences, Pusan National University, Busan 46241, Korea.; Institute of Systems Biology, Pusan National University, Busan 46241, Korea., Lee YJ; Department of Integrated Biological Sciences, Pusan National University, Busan 46241, Korea.; Institute of Systems Biology, Pusan National University, Busan 46241, Korea., Bae WH; Department of Integrated Biological Sciences, Pusan National University, Busan 46241, Korea.; Institute of Systems Biology, Pusan National University, Busan 46241, Korea., Lee DH; Department of Integrated Biological Sciences, Pusan National University, Busan 46241, Korea.; Institute of Systems Biology, Pusan National University, Busan 46241, Korea., Kim HS; Institute of Systems Biology, Pusan National University, Busan 46241, Korea.; Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan 46241, Korea.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Sep 18; Vol. 23 (18). Date of Electronic Publication: 2022 Sep 18.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: MicroRNAs*/genetics , Neoplasms*/genetics, Alternative Splicing ; Codon, Terminator ; DNA Transposable Elements/genetics ; Epigenesis, Genetic ; Humans
مستخلص: Alternative splicing of messenger RNA (mRNA) precursors contributes to genetic diversity by generating structurally and functionally distinct transcripts. In a disease state, alternative splicing promotes incidence and development of several cancer types through regulation of cancer-related biological processes. Transposable elements (TEs), having the genetic ability to jump to other regions of the genome, can bring about alternative splicing events in cancer. TEs can integrate into the genome, mostly in the intronic regions, and induce cancer-specific alternative splicing by adjusting various mechanisms, such as exonization, providing splicing donor/acceptor sites, alternative regulatory sequences or stop codons, and driving exon disruption or epigenetic regulation. Moreover, TEs can produce microRNAs (miRNAs) that control the proportion of transcripts by repressing translation or stimulating the degradation of transcripts at the post-transcriptional level. Notably, TE insertion creates a cancer-friendly environment by controlling the overall process of gene expression before and after transcription in cancer cells. This review emphasizes the correlative interaction between alternative splicing by TE integration and cancer-associated biological processes, suggesting a macroscopic mechanism controlling alternative splicing by TE insertion in cancer.
References: Mol Med Rep. 2018 Sep;18(3):3366-3374. (PMID: 30066876)
J Oncol. 2021 May 4;2021:9966744. (PMID: 34035814)
Int J Mol Sci. 2020 Feb 25;21(5):. (PMID: 32106563)
Genes Cells. 2016 Feb;21(2):185-99. (PMID: 26791143)
Life (Basel). 2020 Jun 25;10(6):. (PMID: 32630504)
Gastroenterol Res Pract. 2020 Aug 13;2020:4159298. (PMID: 32855634)
Cancer Res. 2008 Nov 15;68(22):9525-31. (PMID: 19010929)
Am J Transl Res. 2019 Sep 15;11(9):5338-5356. (PMID: 31632515)
Mol Cancer Ther. 2019 Mar;18(3):579-591. (PMID: 30679387)
Leukemia. 2018 Dec;32(12):2659-2671. (PMID: 29858584)
J Cell Physiol. 2019 Apr;234(4):5153-5162. (PMID: 30362512)
PLoS One. 2011;6(10):e25913. (PMID: 22022465)
Mol Cancer Ther. 2012 Sep;11(9):2010-20. (PMID: 22778155)
Adv Drug Deliv Rev. 2013 Mar;65(3):376-82. (PMID: 22841506)
Nat Genet. 2008 Dec;40(12):1413-5. (PMID: 18978789)
Int J Oncol. 2018 Jun;52(6):1923-1933. (PMID: 29620192)
Cell Death Dis. 2018 Apr 19;9(4):438. (PMID: 29739921)
Front Oncol. 2019 Jul 30;9:653. (PMID: 31417861)
Adv Genet (Hoboken). 2021 Dec 09;3(1):2100022. (PMID: 36619351)
Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13427-32. (PMID: 16938881)
Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4908-4916. (PMID: 30070326)
J Biochem. 2022 Jul 25;172(2):117-126. (PMID: 35652295)
Nat Rev Mol Cell Biol. 2017 Jul;18(7):437-451. (PMID: 28488700)
Sci Rep. 2019 Jan 23;9(1):336. (PMID: 30674935)
PLoS One. 2019 Feb 26;14(2):e0211968. (PMID: 30807603)
Biochem Biophys Res Commun. 2018 Jun 22;501(2):486-493. (PMID: 29746865)
Cancer Lett. 2019 Jul 10;454:224-233. (PMID: 31004703)
Oncotarget. 2016 Feb 2;7(5):5440-60. (PMID: 26713601)
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1894-9. (PMID: 20133837)
Cell. 1993 Aug 27;74(4):597-608. (PMID: 8358789)
J Pathol Transl Med. 2021 Mar;55(2):125-131. (PMID: 33596633)
Oncotarget. 2014 Nov 30;5(22):11054-63. (PMID: 25373410)
Biochim Biophys Acta. 2013 Nov;1829(11):1161-74. (PMID: 23938249)
Hepatology. 2012 Jan;55(1):98-107. (PMID: 21887698)
J Cell Biochem. 2020 Mar;121(3):2258-2267. (PMID: 31693222)
Biochem Biophys Res Commun. 2018 Apr 30;499(1):52-58. (PMID: 29550487)
Transl Lung Cancer Res. 2019 Dec;8(6):862-875. (PMID: 32010565)
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. (PMID: 34754128)
Nature. 1988 May 5;333(6168):87-90. (PMID: 2834650)
Clin Chem. 2006 Feb;52(2):202-11. (PMID: 16384885)
Nat Neurosci. 2019 Oct;22(10):1709-1717. (PMID: 31451803)
Biochim Biophys Acta. 2016 Jan;1859(1):169-76. (PMID: 26149773)
Epigenomics. 2010 Apr;2(2):245-69. (PMID: 22121873)
Gene. 2018 Feb 5;642:354-361. (PMID: 29128635)
Front Biosci (Landmark Ed). 2018 Jan 1;23(7):1292-1309. (PMID: 28930600)
Biosci Rep. 2018 Dec 7;38(6):. (PMID: 30352837)
Tumour Biol. 2016 Jul;37(7):9077-88. (PMID: 26762412)
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):284-293. (PMID: 30305322)
Indian J Clin Biochem. 2019 Jul;34(3):347-351. (PMID: 31391727)
Nature. 2008 Mar 13;452(7184):230-3. (PMID: 18337823)
Gene. 2011 Dec 1;489(1):1-5. (PMID: 21939745)
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2943-8. (PMID: 24294382)
Nat Med. 2009 Sep;15(9):1023-30. (PMID: 19668192)
Cell Biol Int. 2018 Aug;42(8):923-930. (PMID: 28880489)
Genome Biol. 2011;12(1):R9. (PMID: 21251333)
Mol Cell Biol. 1996 Oct;16(10):5518-26. (PMID: 8816464)
Biomed Pharmacother. 2019 May;113:108716. (PMID: 30844657)
J Biomol Screen. 2013 Oct;18(9):1110-20. (PMID: 23771823)
Mol Ecol. 2019 Mar;28(6):1537-1549. (PMID: 30003608)
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):E4726-34. (PMID: 26261309)
Gene. 2019 Jan 30;683:47-53. (PMID: 30300682)
Trends Biochem Sci. 2016 Jan;41(1):33-45. (PMID: 26682498)
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474. (PMID: 32303702)
J Biol Chem. 2009 Oct 9;284(41):27808-27815. (PMID: 19687011)
Cancers (Basel). 2022 Mar 28;14(7):. (PMID: 35406498)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Annu Rev Genet. 2020 Nov 23;54:539-561. (PMID: 32955944)
Cancer Res. 2018 Sep 15;78(18):5287-5299. (PMID: 30042153)
Am J Hematol. 1999 Nov;62(3):150-8. (PMID: 10539881)
Curr Opin Plant Biol. 2019 Apr;48:18-25. (PMID: 30849712)
Onco Targets Ther. 2018 Sep 07;11:5569-5577. (PMID: 30237723)
Biochem Biophys Res Commun. 2018 Jan 22;495(4):2482-2489. (PMID: 29269300)
Nucleic Acids Res. 2005 Sep 07;33(16):5026-33. (PMID: 16147986)
Cancers (Basel). 2020 Jul 08;12(7):. (PMID: 32650508)
Cancer Res. 2005 Jul 1;65(13):5761-8. (PMID: 15994951)
J Cancer Res Clin Oncol. 2012 Mar;138(3):363-70. (PMID: 22045472)
Cancers (Basel). 2019 Feb 23;11(2):. (PMID: 30813457)
Arch Med Sci. 2018 Jun;14(4):745-751. (PMID: 30002690)
Carcinogenesis. 2015 Jul;36(7):710-8. (PMID: 25916654)
Cell Signal. 2019 Nov;63:109390. (PMID: 31419576)
Biochem Biophys Res Commun. 2021 Mar 26;546:21-28. (PMID: 33561744)
Cancer Cell. 2018 Aug 13;34(2):211-224.e6. (PMID: 30078747)
Nature. 2011 Nov 23;480(7377):387-90. (PMID: 22113612)
Prostate. 1999 May 15;39(3):166-74. (PMID: 10334105)
Cold Spring Harb Perspect Biol. 2019 Nov 1;11(11):. (PMID: 30765414)
Development. 2016 Nov 15;143(22):4101-4114. (PMID: 27875251)
Hematology. 2018 Dec;23(10):778-784. (PMID: 29757120)
Nat Genet. 2019 Apr;51(4):611-617. (PMID: 30926969)
Br J Haematol. 1999 Dec;107(4):851-60. (PMID: 10606894)
Nucleic Acids Res. 2008 Oct;36(17):5581-90. (PMID: 18757892)
Cancer Lett. 2018 Nov 1;436:10-21. (PMID: 30102952)
FASEB J. 2019 Oct;33(10):10973-10985. (PMID: 31318608)
Prostate. 2014 May;74(6):602-17. (PMID: 24615685)
Chemosphere. 2022 Sep;302:134826. (PMID: 35525455)
J Biol Chem. 2019 Jan 18;294(3):875-886. (PMID: 30482844)
ACS Appl Mater Interfaces. 2018 Nov 21;10(46):39478-39486. (PMID: 30350935)
Trends Genet. 2003 Oct;19(10):530-6. (PMID: 14550626)
J Cell Biochem. 2018 Dec;119(12):10278-10290. (PMID: 30129088)
Carcinogenesis. 2010 Jan;31(1):27-36. (PMID: 19752007)
Cancer Res. 2007 Jun 15;67(12):5635-42. (PMID: 17575129)
Oncogene. 2008 Jan 10;27(3):404-8. (PMID: 17621273)
Mol Med Rep. 2020 Mar;21(3):1517-1526. (PMID: 32016472)
Sci Rep. 2019 Sep 3;9(1):12702. (PMID: 31481751)
Curr Opin Plant Biol. 2018 Apr;42:23-29. (PMID: 29453028)
Diabetes Obes Metab. 2018 Sep;20(9):2075-2084. (PMID: 29749030)
Biochem Biophys Res Commun. 2018 Jul 2;501(4):1060-1067. (PMID: 29777702)
Mol Cell. 2015 Oct 1;60(1):105-17. (PMID: 26431027)
Mol Cell. 2005 Dec 22;20(6):881-90. (PMID: 16364913)
Mol Ther Nucleic Acids. 2021 Feb 24;24:164-174. (PMID: 33767913)
J Hepatol. 2021 Jan;74(1):122-134. (PMID: 32738449)
Mol Ther Nucleic Acids. 2019 Dec 6;18:308-319. (PMID: 31614321)
Trends Genet. 2001 Nov;17(11):619-21. (PMID: 11672845)
Nat Struct Mol Biol. 2011 Jun;18(6):673-9. (PMID: 21552259)
Brief Funct Genomics. 2018 Jul 22;18(4):255-266. (PMID: 30785618)
Bioinformatics. 2015 Jul 15;31(14):2257-61. (PMID: 25735770)
Cancers (Basel). 2019 Mar 13;11(3):. (PMID: 30871206)
Cancer Res. 1992 Feb 1;52(3):643-5. (PMID: 1310068)
Clin Cancer Res. 2009 Sep 1;15(17):5338-49. (PMID: 19706803)
Dis Markers. 2019 Feb 11;2019:7378967. (PMID: 30886656)
Cancers (Basel). 2018 Aug 16;10(8):. (PMID: 30115848)
Genome Res. 2014 Feb;24(2):212-26. (PMID: 24265505)
Mol Cell Biochem. 2018 Feb;439(1-2):95-104. (PMID: 28795314)
Anal Biochem. 2020 Aug 1;602:113781. (PMID: 32485163)
JCI Insight. 2020 Jun 4;5(11):. (PMID: 32493845)
Genes Cancer. 2010 Jun;1(6):629-40. (PMID: 21779462)
Trends Genet. 2006 May;22(5):260-7. (PMID: 16569458)
Cell. 2009 Feb 20;136(4):701-18. (PMID: 19239890)
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1853-1862. (PMID: 32141554)
Dev Cell. 2008 Dec;15(6):813-28. (PMID: 19081071)
BMC Cancer. 2022 Apr 8;22(1):373. (PMID: 35395756)
Oncol Rep. 2019 Feb;41(2):1218-1230. (PMID: 30431113)
BMC Cancer. 2010 Feb 17;10:44. (PMID: 20163738)
Int J Biol Macromol. 2019 Jan;121:214-222. (PMID: 30312695)
Dig Dis Sci. 2021 Nov;66(11):3862-3871. (PMID: 33389349)
Tumour Biol. 2016 Oct;37(10):13369-13376. (PMID: 27460085)
J Cell Physiol. 2018 Sep;233(9):7379-7390. (PMID: 29575013)
Oncogenesis. 2020 Mar 2;9(3):29. (PMID: 32123162)
Cancer Biomark. 2018 Feb 6;21(2):251-260. (PMID: 29171984)
Sci Rep. 2021 Feb 4;11(1):3139. (PMID: 33542430)
Philos Trans R Soc Lond B Biol Sci. 2020 Mar 30;375(1795):20190342. (PMID: 32075558)
Onco Targets Ther. 2018 Mar 23;11:1643-1653. (PMID: 29615839)
EBioMedicine. 2019 Apr;42:340-351. (PMID: 30952616)
J Dermatol Sci. 2018 Nov;92(2):197-206. (PMID: 30262127)
BMC Cancer. 2008 May 02;8:125. (PMID: 18452628)
Clin Exp Metastasis. 2016 Mar;33(3):249-61. (PMID: 26680363)
Mob DNA. 2016 Dec 1;7:24. (PMID: 27980689)
Mod Pathol. 2009 Mar;22(3):442-9. (PMID: 19136926)
EMBO J. 2004 Mar 10;23(5):1133-43. (PMID: 14976556)
Mol Biol Evol. 2005 Aug;22(8):1702-11. (PMID: 15901843)
BMC Genomics. 2020 Mar 17;21(1):237. (PMID: 32183698)
Int J Oncol. 2010 Jan;36(1):39-48. (PMID: 19956831)
Biochem Biophys Res Commun. 2020 Jan 8;521(2):303-309. (PMID: 31668372)
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):968-973. (PMID: 29339519)
Philos Trans R Soc Lond B Biol Sci. 2020 Mar 30;375(1795):20190344. (PMID: 32075563)
Genome Biol. 2021 Sep 14;22(1):265. (PMID: 34521452)
Cancer Res. 2012 Aug 1;72(15):3764-74. (PMID: 22659450)
J Exp Clin Cancer Res. 2019 Feb 22;38(1):98. (PMID: 30795787)
World J Gastroenterol. 2019 Apr 21;25(15):1890-1898. (PMID: 31057302)
Nat Med. 1996 Aug;2(8):912-7. (PMID: 8705862)
Onco Targets Ther. 2020 Aug 05;13:7809-7818. (PMID: 32801784)
Gene. 2013 Apr 15;518(2):231-41. (PMID: 23333607)
J Exp Clin Cancer Res. 2018 Sep 3;37(1):214. (PMID: 30176933)
Cell Prolif. 2019 Mar;52(2):e12548. (PMID: 30507050)
Nature. 1997 May 15;387(6630):299-303. (PMID: 9153396)
Cell Physiol Biochem. 2018;48(4):1735-1746. (PMID: 30078003)
Onco Targets Ther. 2019 Aug 14;12:6525-6534. (PMID: 31616162)
Cancer Cell Int. 2019 Nov 21;19:308. (PMID: 31768130)
Hepatology. 2001 Jul;34(1):55-61. (PMID: 11431734)
Hum Mutat. 2005 Sep;26(3):284. (PMID: 16088935)
Int J Mol Sci. 2020 Feb 10;21(3):. (PMID: 32050713)
J Exp Clin Cancer Res. 2020 Jan 3;39(1):5. (PMID: 31900207)
J Cell Biochem. 2019 May;120(5):6926-6936. (PMID: 30652355)
Free Radic Biol Med. 2020 May 20;152:432-454. (PMID: 31899343)
Int Immunopharmacol. 2022 Oct;111:108918. (PMID: 35905561)
PLoS One. 2014 Feb 04;9(2):e88064. (PMID: 24505377)
Cancers (Basel). 2019 Nov 22;11(12):. (PMID: 31766606)
Cell Signal. 2014 Oct;26(10):2234-9. (PMID: 25025570)
Front Pharmacol. 2019 Jan 10;9:1565. (PMID: 30687106)
RNA. 2014 Oct;20(10):1621-31. (PMID: 25140042)
Int J Mol Med. 2019 Jan;43(1):267-275. (PMID: 30365117)
Nat Commun. 2019 Sep 6;10(1):4022. (PMID: 31492840)
Saudi J Biol Sci. 2018 Jul;25(5):965-970. (PMID: 30108448)
Trends Genet. 1994 Jun;10(6):188-93. (PMID: 8073532)
Gut. 2014 Apr;63(4):635-46. (PMID: 23704319)
Mob DNA. 2012 May 23;3(1):9. (PMID: 22621612)
Genes Dev. 2003 Feb 15;17(4):419-37. (PMID: 12600935)
Nucleic Acids Res. 2021 Oct 11;49(18):10573-10588. (PMID: 34551436)
Biochem Biophys Res Commun. 2019 Jan 8;508(2):527-535. (PMID: 30509491)
Cell Rep. 2013 Jan 31;3(1):103-15. (PMID: 23273915)
Cancer Manag Res. 2020 Sep 30;12:9375-9387. (PMID: 33061626)
Thorac Cancer. 2018 Aug;9(8):939-949. (PMID: 29897167)
Cancer Manag Res. 2018 Aug 13;10:2627-2633. (PMID: 30147363)
Kaohsiung J Med Sci. 2020 Jan;36(1):13-19. (PMID: 31587503)
J Cell Physiol. 2019 Dec;234(12):22742-22752. (PMID: 31127628)
Mutat Res. 1997 Apr;386(2):119-30. (PMID: 9113113)
J Exp Clin Cancer Res. 2018 Sep 18;37(1):230. (PMID: 30227870)
Biomed Pharmacother. 2018 Mar;99:9-17. (PMID: 29324317)
Plant Biotechnol J. 2021 Sep;19(9):1798-1811. (PMID: 33780108)
Nature. 2001 Feb 15;409(6822):860-921. (PMID: 11237011)
Cancer Res. 2006 Apr 15;66(8):4079-88. (PMID: 16618727)
J Biol Chem. 2008 Jan 18;283(3):1229-33. (PMID: 18024428)
Cancer Lett. 2018 Oct 28;435:1-9. (PMID: 30056111)
Stress. 2018 Nov;21(6):575-579. (PMID: 29996702)
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19280-5. (PMID: 23129656)
Cell Prolif. 2019 Mar;52(2):e12551. (PMID: 30485570)
Bioengineered. 2021 Dec;12(2):10126-10135. (PMID: 34978519)
Gastroenterology. 1993 Sep;105(3):820-6. (PMID: 8359652)
Cancer Manag Res. 2020 Jul 22;12:6137-6147. (PMID: 32801863)
Adv Clin Chem. 2010;52:145-67. (PMID: 21275343)
Blood. 2002 Aug 15;100(4):1449-53. (PMID: 12149230)
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188563. (PMID: 33971276)
Cell. 2013 Mar 28;153(1):101-11. (PMID: 23540693)
Biochem Biophys Res Commun. 2018 Dec 2;506(4):793-798. (PMID: 30389135)
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1913-1921. (PMID: 32141560)
Int J Mol Med. 2018 Mar;41(3):1740-1748. (PMID: 29328362)
Science. 2003 May 23;300(5623):1288-91. (PMID: 12764196)
Genes Dev. 2019 May 1;33(9-10):482-497. (PMID: 30842218)
J Ovarian Res. 2019 Dec 9;12(1):121. (PMID: 31815639)
FEBS J. 2022 Mar;289(5):1160-1179. (PMID: 33471418)
PLoS Comput Biol. 2011 May;7(5):e1002046. (PMID: 21573203)
Cell Death Dis. 2018 May 22;9(6):607. (PMID: 29789536)
Int J Mol Sci. 2019 Nov 15;20(22):. (PMID: 31731828)
Nat Rev Cancer. 2017 Jul;17(7):415-424. (PMID: 28642606)
Nature. 1997 May 15;387(6630):296-9. (PMID: 9153395)
Br J Cancer. 2004 Aug 31;91(5):985-94. (PMID: 15292941)
Tumour Biol. 2019 Mar;41(3):1010428319826853. (PMID: 30887897)
Cell Death Dis. 2018 Aug 6;9(8):831. (PMID: 30082743)
Mol Cell Biol. 2003 Feb;23(4):1175-80. (PMID: 12556478)
Mol Carcinog. 2018 Aug;57(8):1067-1077. (PMID: 29667779)
Gene. 2019 May 20;697:26-34. (PMID: 30772516)
Oncol Rep. 2015 Jun;33(6):2845-52. (PMID: 25873329)
Biomed Pharmacother. 2018 Nov;107:424-432. (PMID: 30103114)
J Mol Biol. 2004 Aug 20;341(4):883-6. (PMID: 15328599)
Sci Transl Med. 2013 Jan 23;5(169):169ra12. (PMID: 23345610)
Nat Rev Mol Cell Biol. 2005 May;6(5):386-98. (PMID: 15956978)
Cancer Discov. 2013 Nov;3(11):1228-37. (PMID: 24145039)
Bioessays. 2008 Jan;30(1):38-47. (PMID: 18081010)
Science. 2012 Aug 24;337(6097):967-71. (PMID: 22745252)
Immunity. 2012 Nov 16;37(5):930-46. (PMID: 23123061)
World J Gastroenterol. 2019 Sep 21;25(35):5300-5309. (PMID: 31558874)
Mol Med Rep. 2018 Mar;17(3):4581-4588. (PMID: 29328399)
Genome Res. 2002 Jul;12(7):1060-7. (PMID: 12097342)
Methods Mol Biol. 2019;1907:161-170. (PMID: 30542999)
Cancer Res. 1993 Oct 15;53(20):4754-6. (PMID: 7691404)
Oncogene. 2010 Oct 28;29(43):5775-84. (PMID: 20562909)
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12359-64. (PMID: 19590016)
Mol Cell. 2013 Dec 12;52(5):720-33. (PMID: 24332178)
FEBS J. 2010 Feb;277(4):856-66. (PMID: 20082635)
Int J Oncol. 2010 Feb;36(2):331-40. (PMID: 20043066)
Front Chem. 2016 Feb 11;4:6. (PMID: 26904537)
Biosci Rep. 2019 Jan 3;39(1):. (PMID: 30254102)
Stem Cell Reports. 2014 Jan 14;2(1):26-35. (PMID: 24511468)
فهرسة مساهمة: Keywords: TE; alternative splicing; cancer; miRNA derived from TE
المشرفين على المادة: 0 (Codon, Terminator)
0 (DNA Transposable Elements)
0 (MicroRNAs)
تواريخ الأحداث: Date Created: 20220923 Date Completed: 20220926 Latest Revision: 20240904
رمز التحديث: 20240904
مُعرف محوري في PubMed: PMC9502224
DOI: 10.3390/ijms231810918
PMID: 36142830
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms231810918